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Introduction
Ductular reactions (DRs) comprise cellular reactions of ductu-
lar phenotype at the portal-parenchymal interface and can be 
observed in response to acute or chronic injury in virtually all 
forms of human liver disease (1, 2). There is a marked diversity 
in DRs with respect to morphological appearance as well as their 
putative cellular origin, possibly reflecting the mode of injury. It 
is widely accepted that, in most cases, DRs arise from the biliary 
compartment, either from mature bile ducts or their outermost 
terminals, the canals of Hering (1, 3, 4). Hence, ductular reactive 
cells (DRCs) arise periportally and express biliary proteins, such as 
CK19, EpCAM, CD133, SOX9, or A6 (rodents). However, hepato-
cytes may also give rise to DRCs by undergoing biliary metaplasia 
in response to injury (5–8) and have recently even been proposed 
to be the main cellular source for DRs in distinct injury models (9).
The explicit functional relevance of DRs in liver disease is 
not entirely understood. Data derived from histomorphology and 
in vitro studies have long suggested that DRs may contain pro-
genitors that normally reside in a quiescent state in the canals of 
Hering of the normal liver and have led to the frequent synony-
mous use of the terms DRCs, liver progenitor cells (LPCs), or 
adult hepatic stem cells. It is widely believed that such putative 
progenitors serve as an adult emergency compartment capable of 
producing both cholangiocytes and hepatocytes in case acute or 
chronic liver injury compromises self-duplication of these mature 
epithelial cells. While the biliary fate is considered the “default 
setting” of DRCs determined by juxtacrine NOTCH activation, 
paracrine activation of β-catenin by WNT proteins may alter the 
fate of biliary-derived DRCs such that they become hepatocytes 
(10–12). In line with this concept of DRCs physiologically acting 
as bipotential progenitors, cells isolated from DRs can self-renew, 
give rise to biliary cells and hepatocytes in vitro, and regenerate 
hepatocytes with variable success when transplanted into Fah–/– 
mice, a mouse model of hereditary tyrosinemia type 1 (13–16). Yet, 
recent attempts to address the capacity of DRCs to act as physi-
ological progenitors to regenerate hepatocytes after short-term 
liver injury using genetic lineage-tracing methods have revealed 
conflicting results (14, 17–23). Beyond liver repair, LPCs have 
also come into focus as a likely candidate cellular compartment 
susceptive to malignant transformation and that can give rise to 
hepatocellular carcinoma (HCC) or cholangiocarcinoma (24, 25); 
however, evidence from compartment-specific lineage-tracing in 
vivo models that supports the view that HCCs originate from an 
adult LPC compartment does not exist.
Here, by using a highly specific lineage-tracing system for the 
adult biliary compartment that allows efficient long-term track-
ing of DRs in a broad range of different liver injury models, we 
provide a comprehensive analysis to define the histogenesis of 
DRs and their prospective cellular fate in liver regeneration and 
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To assess whether DRs are the progeny of the HNF1β+ ductal 
compartment, HNF1β lineage-labeled R26Tom Hnf1b-CreER ani-
mals were subjected to 2 to 3 weeks of various liver injury models 
known to elicit a DR after predominantly biliary (bile duct ligation 
[BDL]; methylene dianiline [MDA] treatment), mixed hepatocellu-
lar-cholestatic (3,5-diethoxycarbonyl-1,4-dihydrocollidine [DDC] 
diet), or hepatocellular injury (choline-deficient ethionine-supple-
mented [CDE] diet) models. In addition to these exogenous models, 
we used a genetic mouse model of chronic hepatocellular-choles-
tatic injury (Mdr2–/– R26Tom Hnf1b-CreER animals; tamoxifen treat-
ment at P21) analyzed at P60 (Figure 2A). Irrespective of the injury 
model used, we found up to 85% CK19+ DRCs costaining for tdTom 
(Figure 2, B and C), indicating that the vast majority of DRCs arise 
from the ductal HNF1β+ compartment. Notably, tdTom/HNF4α 
costaining did not reveal significant neogenesis of hepatocytes from 
DRCs in our injury models, with the exception of the 2-week CDE 
model, in which a very small fraction (0.04% ± 0.019%) of tdTom+/
HNF4α+ hepatocytes was observed (Figure 2, B and C).
The DDC and CDE models are considered prototypical mouse 
“oval cell models” that produce bipotential LPCs; however, their 
potential and quantitative contribution to reparative hepatocyte 
neogenesis remains controversial (10, 14, 17–23). Neither introduc-
ing a 2-week recovery period (DDC diet for 2 weeks plus 2 weeks 
recovery) nor prolonging DDC feeding (DDC diet for 4 weeks) 
carcinogenesis and close important knowledge gaps within this 
controversial field.
Results
DRs arise from biliary HNF1β+ cells in a broad range of liver injury 
models. In the postnatal liver, HNF1β is expressed in bile ducts and 
periportal ductules of the canals of Hering. HNF1β+ cells costained 
for the biliary markers CK19 and SOX9 but showed no overlapping 
staining with the hepatocyte marker HNF4α (Figure 1A and ref. 
7). These observations suggest that HNF1β expression discrim-
inates between cells of the biliary and hepatocyte compartment 
in the postnatal liver. We also found intense HNF1β staining of 
DRCs after different liver injuries, prompting us to trace the fate 
of postnatal biliary HNF1β+ cells as putative precursors of DRs in 
liver injury. We have previously shown that tamoxifen-inducible 
expression of the red fluorescent dye tdTomato (tdTom) (26) in 
adult R26Tom Hnf1b-CreER animals allows highly specific and 
efficient lineage labeling of the HNF1β+ biliary compartment (7). 
Here, tdTom labeling efficiency of the biliary compartment was 
consistently approximately 84%, as assessed by costaining for 
HNF1β, CK19, or SOX9 1 week after a single tamoxifen injection 
(i.p., 100 μg/g BW) in 4- to 5-week-old R26Tom Hnf1b-CreER ani-
mals, while tdTom expression in hepatocytes was an extremely 
rare event, found in <1:8,000 HNF4α+ hepatocytes (Figure 1B).
Figure 1. Efficient and specific inducible lineage labeling of the biliary compartment in R26Tom Hnf1b-CreER animals. (A) In the adult mouse, HNF1β was 
specifically expressed in bile ducts and biliary ductules/canals of Hering (arrows). HNF1β+ cells were identical with SOX9+ and CK19+ cells, as assessed by 
co-IF (HNF1β+/SOX9+: 97.04% ± 0.52%, n = 3; HNF1β+/CK19+: 99.89% ± 0.10%, n = 5), while HNF1β expression in HNF4α+ hepatocytes was virtually absent 
(0.008% ± 0.004%, n = 8). (B) Cre-induced expression of the fluorescent dye tdTom was determined in 5- to 6-week-old R26Tom Hnf1b-CreER reporter mice 
7 days after a single tamoxifen injection. tdTom expression was restricted to HNF1β+/SOX9+/CK19+ bile ducts and periportal ductules (n = 5), whereas 
labeling of HNF4α+ hepatocytes was a rare event (0.012% ± 0.003%, n = 10). All periportal areas revealed a high tdTom labeling efficacy of the HNF1β+ 
compartment (>30 portal tracts per mouse were quantified at ×600 magnification from 3 discontinuous sections; mean labeling efficiency: 84.3% ± 0.6%; 
n = 5 animals). BD, bile duct; PV, portal vein; Tam, tamoxifen. Scale bar: 20 μm.
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Figure 2. DRs arise from the biliary HNF1β+ compartment in a broad range of liver injury models. (A) Seven days after tamoxifen injection, R26Tom 
Hnf1b-CreER mice were subjected to 2 to 3 weeks of various short-term liver injury models (DDC diet, BDL, MDA, CDE diet). For fate mapping of DRs in 
MDR2-deficient mice, Mdr2–/– R26Tom Hnf1b-CreER animals received tamoxifen at week 3 to 4 and were analyzed at week 8. (B) In all models, characteristic 
DRs were assessed by IHC for CK19. Regardless of the mode of injury co-IF analysis revealed tdTom expression in most CK19+ cells, while expression of 
tdTom in HNF4α+ hepatocytes was consistently only observed in the CDE model (yellow arrows). (C) Colocalization (mean value ± SEM) of tdTom+/CK19+ 
and tdTom+/HNF4α+ cells expressed as percentage colocalization (DDC diet, n = 9; BDL, n = 4; MDA, n = 4; Mdr2–/–, n = 4; CDE diet, n = 5). n.d., not detected. 
Scale bar: 100 μm (first and third rows); 20 μm (second, fourth, and fifth rows).
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tocytes in the Sox9-CreER mouse strain most likely results from 
tamoxifen-induced activation of the Cre-driving Sox9 promoter 
in normally SOX9– hepatocytes (4, 20). Although this significant 
overlap of cellular compartments prevents the use of this mouse 
strain to trace the fate of biliary-derived SOX9+ ductal cells as they 
differentiate to hepatocytes, it allows lineage tracing of zone 1 
hepatocytes to reappraise the “streaming liver” hypothesis coined 
by Zajicek 30 years ago (32). However, the fraction of tdTom+ 
hepatocytes in tamoxifen-treated R26Tom Sox9-CreER livers did 
not change significantly after 6 months, and tdTom+/HNF4α+ 
hepatocytes did not leave zone 1 (Supplemental Figure 2, A and 
B). From these two different lineage-tracing models, we conclude 
that during normal liver homeostasis there is no “streaming” of 
hepatocytes, which are constantly renewed either by SOX9+/
HNF1β+ ductal progenitors or by periportal zone 1 hepatocytes.
DRCs do not significantly contribute to hepatocyte regeneration 
after long-term injury. After demonstrating that DRs do not sig-
nificantly contribute to hepatocyte regeneration after short-term 
injury, we sought to characterize their regenerative capacity in 
long-term injury, a time period when progenitor-derived hepa-
tocytes are speculated to accumulate. For this, we traced tdTom 
lineage-labeled DRCs after DDC or CDE long-term treatment or 
in mice lacking the MDR2 transporter. In contrast to livers with 
short-term DDC treatment, livers treated with DDC diet for 3 
and 8 months displayed increasingly more parenchymal damage, 
accompanied by accumulative DRs that adapted a more string-
like morphology radiating into zone 2 and 3 (Figure 3A). However, 
even after 8 months of DDC treatment, we did not detect a rele-
vant number of tdTom+ hepatocytes (Figure 3B). Likewise, livers 
of Mdr2–/– R26Tom Hnf1b-CreER animals displayed large areas of 
tdTom+/CK19+ DRs after 6 and 12 months but lacked a signifi-
cant number of tdTom+/HNF4α+ hepatocytes (Figure 3, A and 
B). The most intense DR expansion was observed after 4 months 
of CDE treatment, the outermost tolerable treatment duration 
(CDE feeding had to be discontinued prematurely in 4 of 10 ani-
mals according to ethical guidelines). We found that the entire 
liver parenchyma (zones 1–3) was infiltrated by tdTom+/CK19+/
A6+ DRCs. Livers were typically small, and the number of hepa-
tocytes per high-power field was greatly reduced (92.0 ± 5.6 hepa-
tocytes vs. 237.7 ± 29.9 hepatocytes per ×200 high-power field in 
age-matched controls) due to hepatocyte hypertrophy, indicating 
insufficient hepatocyte proliferation. Nevertheless, even in this 
severe long-term model with extensive parenchymal damage and 
high mortality, we did not detect a substantial number of tdTom+/
HNF4α+ hepatocytes (1.51% ± 0.53%) derived from the putative 
LPC compartment (Figure 3, A and B).
Notably, hepatocyte Ki67 labeling indices of up to 10% in short- 
and long-term injury were observed in DDC-treated R26Tom Hnf1b- 
CreER or Mdr2–/– R26Tom Hnf1b-CreER animals (summarized in 
Supplemental Figure 3A), indicating that hepatocyte replication is 
effective for hepatocyte repair in these models. In contrast, taking 
into account the extensive parenchymal injury observed in CDE-
treated animals, Ki67 labeling of tdTom– hepatocytes was extremely 
low in the short-term model (CDE diet for 3 weeks: 0.21% ± 0.13%) 
and in the long-term model (CDE diet for 4 months: 1.86% ± 0.39%; 
Supplemental Figure 3B). The Ki67 index of tdTom+ hepatocytes 
compared with that of tdTom– hepatocytes was higher in the CDE 
produced a relevant number of tdTom+/HNF4α+ hepatocytes 
(Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI78585DS1). In contrast, prolong-
ing CDE diet produced 0.13% ± 0.05% tdTom+ hepatocytes (CDE 
diet for 3 weeks) and 2.12% ± 0.48% HNF4α+/tdTom+ hepato-
cytes after introducing a recovery phase (CDE diet for 3 weeks plus 
2 weeks recovery) (Supplemental Figure 1B). Although 2/3 partial 
hepatectomy (PH) is considered the prototypical model for liver 
mass regeneration by self-renewal of hepatocytes, recent data 
proposed that DRCs contribute to hepatocyte neogenesis in this 
model (17, 18). However, even after extended 80% PH (27), we did 
not find hepatocyte regeneration from biliary progenitors (Supple-
mental Figure 1C, left). Further, 2/3 PH preceded by pretreatment 
of mice with retrorsine, used to inhibit hepatocyte replication in 
mice (28), elicited a moderate tdTom+ DR that did not significantly 
contribute to hepatocyte neogenesis (Supplemental Figure 1C, 
right). Notably, liver mass recovery in this model was normal but 
was mainly achieved by hepatocyte hypertrophy, as the number 
of hepatocytes per high-power field was greatly reduced after PH 
when compared with that of controls (83.5 ± 9.4 hepatocytes vs. 
196.7 ± 4.8 hepatocytes per ×200 high-power field; n = 4 and n = 3).
We found generation of hepatocytes from DRCs to be a rare 
event after short-term injury and restricted to the CDE model. 
Thus, our results suggest that DRCs derived from the HNF1β+ com-
partment rarely act as hepatocyte progenitors. In addition, con-
flicting data exist with regard to the contribution of such progeni-
tors to hepatocyte turnover during normal homeostasis (4, 17–19, 
29). When R26Tom Hnf1b-CreER animals were analyzed 6 months 
after tamoxifen treatment, we did not detect duct-derived hepa-
tocytes, as assessed by tdTom/HNF4α costaining (Supplemental 
Figure 2, A and B). We also used a Sox9-CreER mouse strain to 
trace the fate of HNF1β+/SOX9+ cells (14, 30). Like HNF1β, SOX9 
expression is restricted to intrahepatic bile ducts and ductules 
showing no overlap with the HNF4α+ hepatocyte compartment in 
postnatal mice (4, 7, 31). However, tamoxifen injection into R26Tom 
Sox9-CreER animals resulted not only in effective tdTom label-
ing of biliary cells but also in consistent labeling of 1 to 2 layers of 
periportal zone 1 hepatocytes (Supplemental Figure 2, A and B). 
As suggested previously, this “ectopic” labeling of periportal hepa-
Figure 3. Minimal contribution of DRCs to hepatocyte neogenesis after 
long-term liver injury. (A) We traced the fate of lineage-labeled DRs in 
R26Tom Hnf1b-CreER animals after prolonged DDC diet (up to 8 months) or 
CDE diet (4 months) as well as lineage-labeled DRs in Mdr2–/– R26Tom  
Hnf1b-CreER animals (up to 12 months). Despite dramatic expansions of 
A6+ (IHC) or tdTom+/CK19+ (IF) DRs in all long-term injury models, only 
mice fed CDE diet for 4 months displayed a small fraction of HNF4α+ hepa-
tocytes coexpressing tdTom (IF, yellow arrows). Representative pictures are 
shown of n = 4 to 6 animals analyzed per group. (B) Proportion of HNF4α+ 
hepatocytes that coexpress tdTom. tdTom+/HNF4α+ hepatocytes (mean 
value ± SEM) were quantified from n = 4 to 6 animals per group. (C) In the 
DDC model, IHC analysis for A6 and SOX9 shows hepatocytes and cells of 
intermediate morphology that express biliary markers (arrows and arrow-
heads in IHC panels), with increasing time of injury surrounding typical A6+ 
DRs. Co-IF analysis for tdTom, A6, and SOX9 revealed no coexpression of 
tdTom in A6+ or SOX9+ hepatobiliary cells (arrows and asterisks), indicating 
their hepatocyte origin (for quantification, refer to Supplemental Figure 5). 
Scale bar: 100 μm (top 2 rows, A); 20 μm (bottom 2 rows, A, and C).
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Figure 4. DDC-induced DRs do not escape their biliary fate after genetic ablation of NOTCH and/or activation of WNT/β-catenin signaling. (A) For HNF1β 
compartment-specific genetic deletion of the NOTCH-adaptor protein RBP-Jκ and/or stable expression of the WNT effector β-catenin, R26Tom Rbpjfl/fl 
Hnf1b-CreER (n = 8), R26Tom CatnbΔex3 Hnf1b-CreER (n = 5), and R26Tom CatnbΔex3 Rbpjfl/fl Hnf1b-CreER (n = 4) animals were injected with tamoxifen (i.p., 100 
μg/g BW at week 5) and subjected to 2 weeks of DDC diet (week 6–8). Equally treated R26Tom Hnf1b-CreER animals (n = 8) served as controls. Represen-
tative co-IF images for tdTom, tdTom/CK19, tdTom/Ki67, and tdTom/acetylated tubulin are shown that demonstrate reduced proliferative expansion and 
impaired biliary maturation of tdTom+ DRCs after both NOTCH inactivation and/or WNT/ β-catenin activation (arrows indicate tdTom+ DRCs that coexpress 
Ki67 or acetylated tubulin). In all models, DRCs failed to undergo lineage conversion to hepatocytes, as assessed by tdTom/HNF4α co-IF analysis. (B) 
Quantification of co-IF data (mean value ± SEM expressed in percentage; *P < 0.05, **P < 0.01, ***P < 0.001 [1-way ANOVA followed by Tukey’s post-
test]). Scale bar: 100 μm (first column); 20 μm (second through fifth columns).
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long-term model (positive trend in short-term models), suggesting 
that, besides DRC-to-hepatocyte differentiation, more effective 
proliferative expansion of DR-derived hepatocytes may contribute 
to the small increase of tdTom+/HNF4α+ hepatocytes in the CDE 
diet models (Supplemental Figure 3B).
In all models, we found no evidence that lineage-marked 
tdTom+ DRs had emerged from mesenchymal cells or expressed 
mesenchymal markers during the course of injury (Supplemental 
Figure 4). Remarkably, in long-term DDC treatment, we observed 
a growing number of A6+ (and/or SOX9+) hepatocytes and cells 
of intermediate morphology (hepatobiliary cells), which were not 
found in the Mdr2–/– or CDE models (Figure 3C and Supplemen-
tal Figure 5A). These cells surrounded typical A6+/CK19+ DRs 
and could be interpreted to represent progenitors entering the 
hepatocyte lineage by light microscopy. However, we did not find 
DDC-induced A6+/HNF4α+ hepatocytes or hepatobiliary cells 
that costained for tdTom (Figure 3C), clearly demonstrating their 
hepatocyte origin. These hepatocyte-derived A6+/HNF4α+ cells 
may further maturate to CK19+/HNF4α– biliary cells and contrib-
ute to the CK19+ DRs after long-term DDC, as recently suggested 
by hepatocyte fate mapping (6, 8). However, the absolute contri-
bution of hepatocyte-derived DRCs to DDC-induced CK19+ DRs 
was low, even after 8 months of DDC long-term treatment, as 
the proportion of tdTom+/CK19+ DRs decreased by only approx-
imately 15% (Supplemental Figure 5B).
Tamoxifen-inducible mouse models used for lineage tracing 
require careful characterization to ensure correct data interpreta-
tion (33). Different CreER strains may exhibit highly variable sensi-
tivity to tamoxifen-induced reporter expression, depending on the 
strength of the Cre-driving promoter and the respective reporter 
strain used (34). Further, the possibility of tamoxifen-indepen-
dent reporter expression as well as de novo recombination events 
caused potentially by tamoxifen that was not eliminated during 
injury must be considered. In our system, this Cre activation, per-
petuated by remnant tamoxifen after the 7-day washout period, 
could lead to de novo labeling of HNF1β-expressing ductal cells 
but also potentially mark injury-induced HNF1β-expressing hepa-
tocytes. This might lead to both underestimating the contribution 
of nonbiliary compartments to DRs and overestimating the num-
ber of duct-derived hepatocytes. However, we only found tamox-
ifen-dependent reporter expression in both homeostasis and 
injury (Supplemental Figure 6). Further, experiments measuring 
nuclear translocation of Cre, reporter expression over time, and 
HNF1β expression in nonductal compartments during injury (Sup-
plemental Figure 7, A–F) as well as tamoxifen-spiking experiments 
(Supplemental Figure 7, G and H) oppose the concern of de novo 
reporter labeling of DRCs or hepatocytes after the 7-day washout 
as used throughout our study (refer to legend of Supplemental Fig-
ure 7 for a detailed description).
In vivo genetic modulation of NOTCH and/or WNT/β-catenin 
signaling do not redirect DRs from biliary differentiation toward the 
hepatocyte lineage. Our results challenge the view that the primary 
function of DRs is as progenitors to regenerate damaged hepa-
tocytes and rather imply that the biliary fate of DRs in the post-
natal mouse is firmly determined with limited plasticity over a 
broad range of acute and chronic injury modes. However, a highly 
reputed concept has been developed recently, implying that the 
opposing activities of NOTCH and WNT/β-catenin signaling 
within DRCs are regulated by the DR-surrounding cellular niche 
and dictate the cellular differentiation of DRCs toward biliary 
cells or hepatocytes (10). This attractive and potentially clinically 
relevant hypothesis lacks confirmation from formal lineage trac-
ing. Therefore, we combined our lineage-tracing approach with 
genetic inactivation of canonical NOTCH by deleting the essen-
tial NOTCH effector RBP-Jκ and/or activation of the WNT/β-cat-
enin signaling pathway by expressing a nondegradable mutant of 
β-catenin specifically within the tdTom-labeled biliary com-
partment, hypothesizing that these genetic modifications would 
instruct DRCs toward the hepatocyte lineage.
We found the HNF1β+ biliary compartment morphologically 
unaltered and no tdTom+/HNF4α+ hepatocytes when R26Tom 
Rbpjfl/fl Hnf1b-CreER animals were analyzed up to 24 weeks after 
tamoxifen treatment, suggesting that canonical NOTCH is not 
absolutely required to maintain the biliary fate of bile ducts and 
ductules in normal homeostasis (data not shown). However, after 
DDC treatment, R26Tom Rbpjfl/fl Hnf1b-CreER animals displayed a 
blunted tdTom+ DR, as assessed by morphometric analysis (Figure 
4, A and B). Effective and specific genetic deletion of Rbpj within 
DDC-induced DRCs was confirmed by IHC analysis (Supplemen-
tal Figure 8A). Further, expression of the proliferation marker 
Ki67 and the cilia marker acetylated tubulin was reduced within 
RBP-Jκ–deficient tdTom+ DRCs (Figure 4, A and B), indicating 
that NOTCH is required for both effective expansion and biliary 
maturation of DRs. However, inactivation of NOTCH does not 
suffice to convert DDC-induced DRCs to hepatocytes, as tdTom+/
HNF4α+ hepatocytes were virtually absent (Figure 4, A and B).
Next, we analyzed mice expressing a nondegradable form 
of the WNT effector β-catenin within the tdTom-labeled ductal 
compartment (R26Tom CatnbΔex3 Hnf1b-CreER mice). In these mice, 
tamoxifen treatment resulted in robust nuclear and cytoplasmic 
staining of β-catenin in DDC-induced DRCs (75.0% ± 1.3%) as 
compared with that in livers from equally treated R26Tom Hnf1b- 
CreER animals (3.38% ± 0.58%; Supplemental Figure 8B). Yet, 
this also failed to generate DRC-derived tdTom+/HNF4α+ hepa-
tocytes (Figure 4, A and B). Even after simultaneous inactivation 
of Rbpj and expression of stabilized CatnbΔex3 in DDC-induced 
DRCs (R26Tom CatnbΔex3 Rbpjfl/fl Hnf1b-CreER mice), we failed to 
detect a significant number of tdTom+/HNF4α+ hepatocytes. 
These findings support the view that the biliary identity of post-
natal DRs is rather static, with low potential to adopt a hepatocyte 
fate. Notably, β-catenin activation had similar inhibitory effects on 
DR expansion and biliary maturation as did NOTCH inhibition in 
the DDC model (Figure 4B), whereas IHC/immunofluorescence 
(IHC/IF) analysis of progenitor markers, such as CD133 or CD44, 
revealed similar expression in DRCs across all genotypes analyzed 
in Figure 4 (data not shown).
DRCs do not give rise to tumors in selected genetic or genotoxic 
mouse HCC models. The HCC cell type(s) of origin is unknown. 
Human and rodent HCCs may display progenitor cell gene sig-
natures and/or contain LPC-like cells with cancer stem cell fea-
tures (35). Consequently, adult bipotential LPCs have increasingly 
emerged as candidate cells for malignant transformations that 
give rise to HCC (24, 25). In support of this concept, p53-deficient 
or H-RAS/SV40LT-transduced isolated DRCs can generate HCC 
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
2 4 5 2 jci.org   Volume 125   Number 6   June 2015
lineage-tracing model, we hypothesized that we would detect 
tdTom+ HCC nodules if adult biliary-derived DRCs were indeed 
targets to malignant transformation in HCC models. Therefore, 
we analyzed R26Tom Hnf1b-CreER animals treated with carcino-
genic diethylnitrosamine (DEN) at P17 that had been pretreated 
with tamoxifen at P10; we confirmed these animals to be equally 
effective in tdTom labeling HNF1β+ biliary cells (analysis at P17: 
92.7% ± 3.8%, n = 3). When analyzed at 10 to 12 months after DEN 
in xenotransplant models (36, 37). However, whether HCCs with 
or without progenitor features arise from transformed progenitors 
or rather from dedifferentiated/transformed hepatocytes, or both, 
is currently unknown (for review see ref. 25).
Although we could not identify a predominant role of bil-
iary-derived DRCs in hepatocyte neogenesis after injury, few 
hepatocytes were DRC derived, indicating bilineage potential 
of at least some DRCs. Due to the high labeling efficacy in our 
Figure 5. DRCs do not give rise to tumors in selected mouse HCC models. (A) R26Tom Hnf1b-CreER animals (tamoxifen at P10) were injected with DEN (25 
mg/kg BW) and analyzed at 10 to 12 months after DEN treatment (n = 6). Representative IHC micrographs of serial sections obtained from one DEN-induced 
tumor nodule stained for collagen IV (Col IV), Ki67, GP73, or AFP. Representative macroscopic transmitted light and fluorescent whole-liver images from 
one DEN-treated animal show all nodular lesions (encircled by dashed lines) negative for tdTom. Co-IF analysis for tdTom and collagen IV revealed sporadic 
tdTom+ DRCs (asterisks) at the tumor margins and within the tumor nodules, but tumor cells never costained for tdTom (tumor nodules obtained from 
different animals are encircled by dashed lines; insets are shown at higher magnification below). (B) Likewise, characterization of tumors observed in Mdr2–/– 
R26Tom Hnf1b-CreER animals (tamoxifen at P21) was performed by IHC for collagen IV, Ki67, GP73, and AFP in 12-month-old animals; nodule formation was 
observed in 4 out of n = 6 animals. Representative serial cryosections of tumor nodules processed from different mice for H&E and co-IF for tdTom and col-
lagen IV indicate tumor cells negative for tdTom (encircled by dashed lines). tdTom+ DRCs (asterisks) are typically observed outside tumor margins and rarely 
found within. Tu, tumor. Scale bar: 1,000 μm (low-magnification H&E, top panel, B); 500 μm (H&E mouse 1–3, B); 100 μm (low-magnification H&E, IHC, and 
top row IF, A; high-magnification H&E, IHC, and top row IF, B); 20 μm (high-magnification H&E and bottom row IF, A; bottom row IF, B).
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about 15%, further corroborating the conception that a minor por-
tion of DRCs derive from hepatocytes. In contrast with our study 
and Yanger’s study, Suzuki and colleagues proposed that the vast 
majority of all DDC-induced CK19+ DRs arise from the hepato-
cyte and not from the biliary compartment, even after short-term 
DDC treatment, when using the Alb-CreER strain (41) to specif-
ically trace the hepatocyte compartment (9). To address these 
discrepancies, we used the identical Alb-CreER mouse strain (41) 
to analyze Cre activity in R26Tom Alb-CreER animals. However, we 
found tdTom reporter activity not only in hepatocytes but also in 
approximately 40% of CK19+ small biliary ductules 1 and 7 days 
after low-dose tamoxifen (Supplemental Figure 9A), indicating 
that Cre expression in Alb-CreER animals lacks hepatocyte spec-
ificity. Consequently, 40% of DDC-induced CK19+ DRs around 
peripheral portal tracts costained for tdTom (Supplemental Figure 
9B), which could erroneously be interpreted to arise from hepato-
cyte-to-biliary conversion.
The concept that adult DRs may harbor facultative liver stem 
cells to replace hepatocytes in case of severe injury has been 
deduced from rat models, in which the liver is forced to regenerate 
by PH after exposure to hepatotoxins such as acetylaminofluorene 
(AAF/PH model), which is thought to abrogate hepatocyte self- 
renewal. In the course of such models, characteristic DRs, tradition-
ally termed “oval cell response,” appear along with hepatobiliary 
cells of transitional morphology, expressing both biliary and hepa-
tocyte markers (42), suggesting that these DRs undergo hepatocyte 
differentiation. In vitro protocols that allow differentiation of iso-
lated DRCs either to biliary cells or hepatocytes support the concept 
of bipotential DRCs/oval cells in the rat liver. Deduced from these 
rat studies, the theory of DRCs/oval cells being capable to serve as 
an SOS compartment for physiologically acting liver stem cells has 
been widely acknowledged as a basic principle of liver regeneration 
(43, 44); however, the lack of adequate lineage-labeling techniques 
in rats prohibits such definite conclusion (45).
Support for the theory of adult biliary-derived DRs having high 
bipotential capacity was provided by Furuyama et al., who per-
formed formal lineage tracing of the biliary compartment using 
an inducible Sox9-CreER knock in mouse (18). They concluded 
that SOX9+ biliary cells give rise to a large fraction of new hepa-
tocytes, not only in various liver injury models, but also in normal 
liver homeostasis, in which they provide a continuous hepatocyte 
supply (18), thereby reviving the controversial “streaming liver” 
hypothesis (32). Neogenesis of hepatocytes from the SOX9 com-
partment has also been reported after DDC diet using a different, 
transgenic Sox9-CreER mouse strain (14) identical to the one used 
in our study. However, biliary compartment specificity of adult 
Sox9-CreER mouse strains has been challenged (4, 20). In line 
with these reports, we found periportal reporter expression in 9% 
of hepatocytes. Furthermore, subsequent studies fate mapping 
the biliary compartment using different transgenic mouse models 
(Opn-CreER or Hnf1b-CreER) found no contribution of the biliary 
compartment or DRCs to homeostatic hepatocyte turnover and 
very limited contribution to hepatocyte neogenesis after short-
term liver injury (19, 21).
Although the quantity of DR-derived hepatocytes after short-
term injury was low in these mouse studies (19, 21), advocates for 
the theory of DRs acting as physiologic progenitors speculated 
injection, livers of all R26Tom Hnf1b-CreER animals displayed tumor 
nodules (mean 6.0 ± 2.8 nodules, n = 6 animals), showing typical 
features of HCC when characterized by histology and IHC mark-
ers, including collagen IV, Ki67, Golgi protein 73 (GP73), and alpha 
fetoprotein (AFP) (Figure 5A). However, macroscopically visible 
HCCs or microscopically identified tumors never expressed fluo-
rescent tdTom when analyzed by fluorescence stereomicroscopy 
or confocal microscopy (Figure 5A). Next, we analyzed HNF1β 
lineage-labeled Mdr2-deficient (Mdr2–/– R26Tom Hnf1b-CreER) 
mice. Mdr2–/– animals are widely used as a genetic model for spon-
taneous, inflammation-induced HCC development (38, 39), with 
extensive activation of progenitors that might undergo malignant 
transformation. Four of six animals analyzed at 12 months had 
developed tumor nodules (mean 4.0 ± 3.1). These tumors were 
highly proliferative and displayed broadening of liver cords, with 
loss of collagen IV, a coarse block pattern of perinuclear GP73, and 
frequent intermingling of AFP+ hepatocytes (Figure 5B). However, 
as in DEN-treated livers, tumor cells in Mdr2–/– R26Tom Hnf1b- 
CreER animals never expressed tdTom in coimmunofluorescence 
(co-IF) analysis (Figure 5B). These data clearly indicate that the 
neoplastic lesions in the DEN and Mdr2–/– HCC models are not 
derived from DRCs but rather originate from hepatocytes.
Discussion
First, our results demonstrate that irrespective of the mode and 
duration of injury, CK19+ DRs arise almost exclusively from the 
adult biliary compartment. Second, DRCs or LPCs do not signifi-
cantly contribute to hepatocyte regeneration in acute or long-term 
chronic liver injury. Third, there is no “streaming liver,” in which 
hepatocytes are continuously replaced by cells originating from 
a progenitor cell niche in the biliary compartment or from zone 1 
hepatocytes in a portal-to-central vein direction. Fourth, genetic 
modulation of the lineage-defining NOTCH and WNT/β-catenin 
signaling pathways cannot release DRCs or LPCs from their bil-
iary fate in vivo. Fifth, tumors in classical genetic or genotoxic 
mouse HCC models do not originate from DRCs.
DRs found in liver disease have been defined as cellular reac-
tions of ductular phenotype but not necessarily of ductular (biliary) 
origin (3). Our results show that such DRs derive from the biliary 
compartment in short-term liver injury models, as the initial high 
fraction of reporter-labeled CK19+ biliary cells was maintained in 
CK19+ DRs. Earlier reports of hepatocytes as an additional source 
for DRCs (5) have recently been confirmed by hepatocyte lineage 
tracing in the setting of cholestatic liver injury (6, 8). This stepwise 
biliary conversion of adult hepatocytes can be induced by genetic 
NOTCH activation (7, 40) and relies on canonical NOTCH sig-
naling upon injury (6). Using AAV-based specific labeling of the 
adult hepatocyte compartment, Yanger et al. found that up to 14% 
of CK19+ DRCs may arise from hepatocytes, with increasing dura-
tion of injury most pronounced in the DDC model (6). Although 
we did not set out to trace hepatocyte fates, the findings with our 
model of hepatocyte reprogramming to CK19+ biliary cells are 
compatible with our biliary fate-tracing model, in which we found 
increasing numbers of A6+ and/or SOX9+ hepatobiliary cells that 
never coexpressed the tdTom reporter in long-term DDC-induced 
injury models. Initial reporter labeling of CK19+ DRs (DDC diet 
for 2 weeks) was consistently reduced after long-term injury by 
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NOTCH and/or β-catenin specifically in DDC-induced DRCs, we 
found altered DR expansion but were unable to divert DRs from 
their biliary fate to become hepatocytes. This supports the concept 
that the biliary fate of DDC-induced DRs is firmly fixed and that 
NOTCH signaling and WNT/β-catenin determine cellular cues for 
effective DR proliferation and morphogenesis (7, 12, 48), rather than 
for DRC lineage allocation. Our findings that neoplastic lesions did 
not arise from the biliary HNF1β lineage in two distinct, commonly 
used HCC mouse models further fits in this overall picture of lim-
ited plastic capacity of postnatal biliary cells and highly suggests 
that hepatocytes are the primary cell type susceptive to malignant 
transformation in hepatocellular carcinogenesis.
Currently, to the best of our knowledge, there is no animal 
model that unequivocally proves the concept that biliary-derived 
DRCs or LPCs physiologically contribute significantly to hepato-
cyte neogenesis in adults, when lineage segregation of the hepa-
tocyte and biliary compartments from hepatoblasts has matured. 
For zebrafish larvae, two highly recognized studies have convinc-
ingly shown that the perinatal biliary compartment can give rise to 
hepatocytes after severe liver damage (49, 50); however, although 
the authors also concluded that this holds true in the adult setting, 
inducible lineage tracing of biliary cells was not included in the 
adult zebrafish studies in either report, precluding the proof of 
such product-precursor relationship.
In all our models, hepatocyte replication was never abolished 
completely. Therefore, we cannot dogmatically rule out that exper-
imental scenarios of liver failure (i.e., after complete and strictly 
hepatocyte-specific growth arrest not affecting the biliary com-
partment), in which DRCs may, in fact, rescue hepatocyte mass, 
as shown in transplantation studies, may exist. Whether such sit-
uations are of relevance for human disease and whether complete 
hepatocyte growth arrest will ultimately imply irrecoverable liver 
failure need to be addressed by future research and novel models. 
Further, the exceptionally high fraction of polyploid hepatocytes 
in mice may confer special resistance and self-renewal capacity to 
the hepatocyte compartment in this species (51). However, consid-
ering the widespread appearance of biliary-derived DRs in multi-
ple mouse injury models, with no or minimal contribution to hepa-
tocyte neogenesis in our study, it seems unlikely that such a highly 
conserved injury response has evolved to chiefly provide a progen-
itor pool for new hepatocytes. The question then arises of the main 
physiological function of DRs. One possible answer is that DRs 
provide an anatomical biliary network to preserve biliary drainage 
from the site of hepatic injury. Limited neogenesis of DR-derived 
hepatocytes and limited biliary conversion of hepatocytes might 
also help to restore the continuity between the hepatocyte cana-
licular system and biliary ductules (52), depending on the type of 
injury. Moreover, even without giving rise to hepatocytes directly, 
DRs (together with their obligatory surrounding mesenchymal 
and inflammatory niche) may well provide important paracrine 
signals that assist self-renewal of hepatocytes.
Although the hypothesis of biliary-derived DRCs serving 
as a physiologically significant cellular backup pool for hepato-
cytes in liver disease still awaits validation, the clonal and bipo-
tential capacity of adult biliary-derived cells in vitro is beyond 
dispute (45). In this context, it has been recently demonstrated 
that human biliary cells obtained from biopsy can be expanded, 
that long-term injury might well lead to accumulation of a relevant 
number of DR-derived hepatocytes. In line with these reports, we 
found negligible (DDC diet, BDL, MDA, Mdr2–/–, 80% PH, ret-
rorsine/PH) or very low (CDE diet) hepatocyte neogenesis from 
DRCs in the short-term injury and regeneration models. However, 
despite dramatic expansion of DRs in 3 different long-term mod-
els, we found virtually no (DDC diet, Mdr2–/–) or minimal (1.5% in 
the CDE model) contribution of DRCs to hepatocyte origination.
In two recent articles, the hepatocyte-producing capacity of 
mouse biliary-derived DRCs was contested completely, even at low 
frequency (22, 23). This conclusion was derived from 2 to 3 weeks 
of short-term CDE diet in models using selective inducible Ck19-
CreER– or AAV8-Cre–mediated lineage labeling of the ductal (~10%–
35% labeling) or hepatocyte (~99% labeling) compartment, and no 
(23) or a negligible number (<0.1%) (22) of DRC-derived hepatocytes 
were detected. Besides the possibility that a subset of DRCs may not 
be marked using the Ck19-CreER strain, experimental conditions, 
including start of the CDE diet in the animals at an older age, may 
also account for the failure to detect rare events of DRC-to-hepato-
cyte differentiation in these studies. In rodents, the magnitude of the 
DR in response to the CDE diet is highly age dependent (46), and lin-
eage maturation of mouse biliary cells is concordant with a decline 
in their capacity to become hepatocytes in vitro after the neonatal 
period (47). At the same time, potential limitations of our model sys-
tem must be considered. Ductal lineage labeling was highly effective 
and specific after a single tamoxifen dose. This specificity was main-
tained during homeostasis, and we found no evidence that remnant 
tamoxifen perpetuates de novo labeling of (injured) cells in our 
models (Supplemental Figure 7), suggesting that the small fraction 
of reporter-expressing hepatocytes observed in the CDE models is 
indeed duct derived. However, we did observe “ectopic” prelabeling 
of hepatocytes, despite this being an extremely rare event (0.012%). 
As basally prelabeled hepatocytes, if detected at all, were exclusively 
found in zone 1, we cannot categorically rule out that the portion of 
labeled hepatocytes had increased in the CDE models as a result of 
selection of zone 1 hepatocytes after differential zonal liver damage 
of predominantly zone 2/3 hepatocytes. Nevertheless, our conclu-
sion that DRC-derived hepatocytes insignificantly contribute to 
short- and long-term injury repair remains intact.
Biliary compartment–derived DRs are highly heterogeneous 
in morphology. Yet, it is unknown whether different morphological 
phenotypes also reflect different cellular origins within the biliary 
compartment. Recent studies demonstrated that the transcriptional 
profiles of isolated DDC- and CDE-induced DRs differ (10, 21), 
and Boulter et al. have convincingly shown that the cellular DR- 
surrounding niche can influence the transcriptome of DRCs (10). 
Presupposing a common precursor of DDC- and CDE-induced 
bipotential DRs, the authors proposed that the balance of NOTCH 
and WNT/β-catenin signaling determines the biliary (NOTCH-
driven) or hepatocyte (WNT/β-catenin–driven) fate of DRCs. To 
support this concept, the authors expressed a stabilized active β-cat-
enin mutant specifically in CK19+ biliary cells and found nuclear 
β-catenin in periportal hepatocytes in the DDC model. Although a 
formal lineage-tracing approach was not implemented, the authors 
concluded that ~10% of all hepatocytes had arisen from lineage 
conversion of primarily biliary-destined DRCs (10). However, when 
combining our lineage-tracing model with genetic modulation of 
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ethanol at 42°C. For hepatocarcinogenesis, male mice received a sin-
gle injection (i.p.) of 25 mg/kg BW of DEN (Sigma-Aldrich) at P17 (59). 
In all experiments, animals were monitored for BW, physical activity, 
grooming routines, levels of alertness, and other signs of stress using 
specific score sheets for each animal model as approved.
IF and IHC. For standard histological and IHC analysis, livers 
were removed, fixed in 4% PFA for 20 hours, embedded in paraffin, 
and sectioned. Serial 3.5-μm-thick sections were stained with H&E 
using standard protocols. IHC was performed with primary antibod-
ies (Supplemental Table 2) followed by diaminobenzidine staining 
(Vector Laboratories) and counterstaining with hematoxylin. For IF 
analysis, livers were fixed in 4% PFA for 2 hours at 4°C; washed in 
PBS; cryoprotected with increasing concentrations of 10%, 20%, and 
30% sucrose solutions prepared in PBS; and embedded in O.C.T. Tis-
sue Tek. Serial 10-μm-thick cryosections were stained with different 
primary antibodies (Supplemental Table 2), followed by fluorescent 
secondary antibodies (Supplemental Table 2) and nuclei costaining 
with DAPI or ToPro3 (pictures were taken with a Zeiss Axiowert 200M 
microscope or confocal Olympus FV10i microscope).
ImageJ software (1.47v) was used to determine the tdTom+ area 
(%). We analyzed 15 to 25 images at a ×100 magnification from ≥3 
discontinuous liver sections obtained from 2 to 3 different liver lobes 
per mouse. Further quantitative analysis of IF data was performed by 
counting tdTom+ coexpression markers (CK19+ or HNF4α+) and all 
positive marker cells; data were expressed as percentages. For this, 
15–25 images per mouse (at ×600 magnification for CK19+ marker 
cells and ×100 magnification for HNF4α+ marker cells) were taken 
from ≥3 liver sections from 2 different lobes and quantified, unless 
otherwise specified in the figure legends.
Statistics. Data are presented as mean value ± SEM. Sample size 
for each experiment is indicated in the figure legends. Statistical com-
parisons were made using either 1-way ANOVA followed by Tukey’s 
post-test or unpaired, 2-tailed Student’s t test with GraphPad Prism 
software. A P value of less than 0.05 was considered significant.
Study approval. Mice were handled and experiments were per-
formed according to the protocols approved by Technische Universität 
München Institutional Animal Care and the veterinarian office of the 
State of Bavaria (Regierung von Oberbayern, approval ID: TVA 55.2-
1-54-2531-55-07 and 55.2-1-54-2532-173-12) according to the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals 
(8th ed. The National Academies Press. 2011.).
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cultivated long-term as organoids, and subsequently converted to 
functional hepatocytes in vitro and in vivo, which may offer enor-
mous therapeutic potential (53). Nevertheless, in the current liter-
ature, there has been an inflationary use of the terms adult “liver 
stem cells” or “liver progenitor cells” for any biliary or progenitor 
marker-expressing DRCs, regardless of their ill-defined biological 
functions. Owing to the fact that, up to now, there is no definite 
evidence that DRCs function as physiologic bipotential progeni-
tors in a quantitatively relevant way in adult liver disease, we dis-
courage the broad use of these terms for DRCs until the explicit 
function of DRCs is firmly established for each setting of injury.
Methods
Animals and tamoxifen treatment. Tamoxifen-inducible Hnf1b-CreER 
(54), Sox9-CreER (30), and Alb-CreER (41) mouse strains all have been 
described previously and were crossed with Ai14-R26lox–STOP–lox–tdTom/+ 
(referred to as R26Tom) reporter mice (26) (The Jackson Laboratory, 
stock 007914) to obtain R26Tom Hnf1b-CreER, R26Tom Sox9-CreER, and 
R26Tom Alb-CreER mice that express the fluorescent dye tdTom upon 
Cre expression. For inducible inactivation of canonical NOTCH signal-
ing, R26Tom Hnf1b-CreER animals were further crossed with mice that 
carry floxed alleles for Rbpj (referred to as Rbpjfl/fl) (55) to obtain R26Tom 
Rbpjfl/fl Hnf1b-CreER mice; analogue interbreedings were performed 
with Catnblox(ex3) animals (56) for conditional expression of a nonde-
gradable active form of β-catenin (R26Tom CatnbΔex3 Hnf1b-CreER ani-
mals) or with multidrug resistance 2 (Mdr2, also known as Abcb4) gene 
knockout (Mdr2–/–) mice (57) (The Jackson Laboratory, stock 002539) 
to obtain Mdr2–/– R26Tom Hnf1b-CreER animals. All mouse strains were 
maintained on a mixed background. For sequences of synthetic oligo-
nucleotides used for genotyping refer to Supplemental Table 1.
To induce Cre activation in Hnf1b-CreER and Sox9-CreER mice, 
tamoxifen (dissolved in corn oil) (Sigma-Aldrich) was injected once 
(i.p.) at 100 μg/g BW into 4- to 5-week-old mice, unless otherwise 
specified in the figure legends. Cre recombinase was activated in Alb-
CreER mice with a single injection of low-dose tamoxifen at 100 ng/g 
BW. In all experimental models, tamoxifen was administered at least 
7 days before different injury models were started.
Models for liver injury, regeneration, and carcinogenesis. For diet- 
induced liver injury, mice were fed a choline-deficient (MP Biomedi-
cals), DL-ethionine-supplemented (0.165% in H2O, Sigma-Aldrich) 
diet (CDE diet) or a DDC diet (0.1% DDC in standard diet, Altromin) 
ad libitum (19). BDL was performed in 8-week-old animals using inha-
lation anesthesia with isoflurane. After midline laparotomy, the com-
mon bile duct was separated from the hepatic artery and ligated twice. 
PH was performed in 7- to 8-week-old animals as described previously 
(27). For 2/3 PH, the left lobe, the left median lobe, and the right median 
lobe were ligated separately and resected. For 80% PH, the lower right 
lobe and one omental lobe were additionally removed. For inhibition 
of hepatocyte proliferation (28) before 2/3 PH, retrorsine (Sigma- 
Aldrich) was added to demineralized water at 10 mg/ml and titrated to 
pH 2.5 with 35% HCl diluted 1:10. The solution was neutralized to pH 
7.0 with 1 M NaOH, and NaCl was added to obtain a concentration of 
0.15 M NaCl. Animals were injected weekly for 2 weeks i.p. at 70 μg/g 
BW before PH was performed. Acute toxic biliary injury was induced 
by i.p. injection of 4,4′-methylene dianiline (MDA/DAPM) 3 times on 
days 0, 3, and 6 at 50 μg/g BW (58). For this, MDA (Sigma-Aldrich) was 
dissolved in 100% ethanol and further diluted to 50 mg/ml in 35% 
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